Cantor Fitzgerald Reiterates “Overweight” Rating for Adlai Nortye (NASDAQ:ANL)

Adlai Nortye (NASDAQ:ANL)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports.

Adlai Nortye Stock Up 1.1 %

Shares of ANL opened at $3.65 on Thursday. The firm’s fifty day simple moving average is $9.81 and its two-hundred day simple moving average is $9.25. Adlai Nortye has a 12 month low of $3.21 and a 12 month high of $19.30.

Hedge Funds Weigh In On Adlai Nortye

An institutional investor recently raised its position in Adlai Nortye stock. Cantor Fitzgerald L. P. increased its holdings in Adlai Nortye Ltd. (NASDAQ:ANL) by 128.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,310 shares of the company’s stock after acquiring an additional 22,644 shares during the period. Cantor Fitzgerald L. P. owned about 0.11% of Adlai Nortye worth $362,000 at the end of the most recent quarter. Institutional investors and hedge funds own 35.21% of the company’s stock.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.